Header

UZH-Logo

Maintenance Infos

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting


Matter-Walstra, K; Schwenkglenks, Matthias; Dedes, K J (2017). Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast Cancer Research and Treatment, 163(3):635.

Statistics

Citations

Dimensions.ai Metrics
3 citations in Web of Science®
3 citations in Scopus®
1 citation in Microsoft Academic
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:June 2017
Deposited On:04 Jan 2018 08:34
Last Modified:19 Feb 2018 09:57
Publisher:Springer
ISSN:0167-6806
OA Status:Closed
Publisher DOI:https://doi.org/10.1007/s10549-017-4209-5
PubMed ID:28321586

Download

Full text not available from this repository.
View at publisher

Get full-text in a library